Modified Delphi Consensus Guidelines for Pelvic Floor Botulinum Toxin Injection.

Urogynecology (Philadelphia, Pa.) 2026 Vol.32(4) p. 312-320

Hufnagel DH, Torosis M, Ackerman AL

관련 도메인

Abstract

[IMPORTANCE] Myofascial pelvic pain (MPP) is an under-treated etiology of pelvic pain, presenting with pelvic floor tender points and/or increased tension. While limited data support off-label use of pelvic floor botulinum toxin (BTA) injections for refractory MPP, clinical guidance on its utilization is lacking.

[OBJECTIVE] We sought to develop consensus-based guidelines for pelvic floor BTA injection.

[STUDY DESIGN] We identified 46 potential experts in the use of pelvic floor BTA injection based on research, clinical volume, and publication of patient-facing materials, 18 of whom agreed to participate. Consensus, defined as at least 70% agreement or disagreement, was determined through 3 rounds of electronic surveys using a modified Delphi method between September 2023 and July 2024.

[RESULTS] A total of 15 practitioners completed the first survey, with most based in the United States (93%), working in academic settings, with Obstetrics and Gynecology training (85%). Expert consensus supports that BTA injection is a third-line therapy for high-tone pelvic floor dysfunction and myofascial pelvic pain. Its use may also be considered for involuntary vaginismus, vestibulodynia, and anismus/dyssynergic defecation. Preprocedural examination is sufficient to localize sites and should palpate the puborectalis, pubococcygeus, iliococcygeus, and obturator internus. Injections of 100-200 units total should focus on areas of increased tenderness/hypertonicity; however, for global symptoms or inability to tolerate examination, templated injections may be used. Experts did not support performing local anesthetic injections to predict responses. Injection is performed transvaginally with each muscle group receiving 20-50 units BTA in divided 1-2 mL injections. Injections are performed bilaterally. Patients should be followed by quantitative pain assessments with repeat injections as needed.

[CONCLUSIONS] Using a modified Delphi method, we describe expert consensus-based guidelines for pelvic floor BTA injection to provide practical guidance for its use.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 2
해부 MPP → Myofascial pelvic pain scispacy 1
해부 puborectalis scispacy 1
해부 pubococcygeus scispacy 1
해부 iliococcygeus scispacy 1
해부 obturator internus scispacy 1
해부 muscle scispacy 1
해부 BTA scispacy 1
합병증 pelvic scispacy 1
합병증 pelvic floor botulinum scispacy 1
합병증 myofascial pelvic scispacy 1
약물 third-line scispacy 1
약물 [IMPORTANCE] Myofascial pelvic pain ( scispacy 1
약물 [OBJECTIVE] scispacy 1
약물 [RESULTS] A scispacy 1
약물 BTA scispacy 1
약물 [CONCLUSIONS] scispacy 1
질환 Pelvic Floor Botulinum scispacy 1
질환 Myofascial pelvic pain scispacy 1
질환 pelvic pain C0030794
Pelvic Pain
scispacy 1
질환 floor botulinum toxin scispacy 1
질환 high-tone pelvic floor dysfunction scispacy 1
질환 involuntary vaginismus scispacy 1
질환 vestibulodynia C0269084
Vulvar Vestibulitis
scispacy 1
질환 anismus/dyssynergic defecation scispacy 1
질환 tenderness/hypertonicity scispacy 1
질환 pain C0030193
Pain
scispacy 1
질환 Pelvic Floor Botulinum Toxin scispacy 1
질환 BTA scispacy 1
기타 pelvic floor scispacy 1
기타 pelvic floor BTA scispacy 1
기타 Patients scispacy 1

MeSH Terms

Humans; Delphi Technique; Consensus; Female; Pelvic Floor; Pelvic Pain; Neuromuscular Agents; Practice Guidelines as Topic; Botulinum Toxins, Type A; Botulinum Toxins; Myofascial Pain Syndromes

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문